Mustang Bio reports 4 of 4 indolent lymphoma patients respond to MB-106 CAR T; dose escalation approved

MUSTANG BIO, INC.

Clinical responses in 4 of 4 indolent lymphoma patients at starting dose 3.3x10^6 CAR T cells/kg; 2 follicular lymphoma patients achieved CR.
Safety Review Committee unanimously approved dose escalation to 1.0x10^7 CAR T cells/kg; only Grade 1 CRS reported.
Fred Hutch trial (n=20 FL) shows 95% ORR, 80% CR; first patient sustained CR >3 years.
Waldenstrom macroglobulinemia cohort (n=6): 2 CR, one ongoing >22 months; no CRS/ICANS >Grade 2.
Pivotal Phase 2 for WM to start mid-2024, top-line data mid-2026; end-of-Phase 1 FDA meeting expected end of 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.